Arvinas Enters Exclusive Strategic License Agreement With Novartis; Arvinas To Receive $150M Upfront Payment & Up To $1.01B In Milestones
Arvinas Enters Exclusive Strategic License Agreement With Novartis; Arvinas To Receive $150M Upfront Payment & Up To $1.01B In Milestones
The deal is for the worldwide development and commercialization of ARV-766, Arvinas' second generation PROTAC androgen receptor (AR) degrader for patients with prostate cancer. The transaction also includes an asset purchase agreement for the sale of Arvinas' preclinical AR-V7 program to Novartis. Arvinas will receive an upfront payment in the aggregate amount of $150.0 million. Under the License Agreement, Arvinas is eligible to receive additional development, regulatory, and commercial milestones of up to $1.01 billion, as well as tiered royalties for ARV-766.
該協議旨在在全球範圍內開發和商業化 ARV-766，這是Arvinas針對前列腺癌患者的第二代PROTAC雄激素受體（AR）降解劑。該交易還包括一項資產購買協議，將Arvinas的臨床前 AR-V7 項目出售給諾華。Arvinas將獲得總額爲1.5億美元的預付款。根據許可協議，Arvinas 有資格獲得高達 10.1 億美元的額外開發、監管和商業里程碑，以及 ARV-766 的分級特許權使用費。
譯文內容由第三人軟體翻譯。